CD274 and non-small cell lung carcinoma: For patients who received first-line ICI monotherapy, the 12- and 24-month OS rates of 72.1% and 57.8% in this study were consistent with 12- and 24-month OS rates of 70.3% and 51.5% in the KEYNOTE-024 clinical trial of first-line pembrolizumab monotherapy for metastatic NSCLC with PD-L1 TPS ≥50% [22].